The Committee reviewed the application for the inclusion of miconazole nitrate buccal tablets1. The Committee recognized that miconazole ointment or cream was already on the Model List, as an antifungal medicine (for topical use). The absence of comparative data for miconazole nitrate buccal tablets and nystatin lozenges was of concern to the Committee. It concluded that, as insufficient evidence was presented as to its comparative advantage in efficacy and safety, miconazole nitrate buccal tablets should not be added to the Model List.
1 The full application is available from the WHO Essential Medicines Library via the Internet at http://mednet3.who.int/mf/.